Fenwick Represents Maze Therapeutics in $140 Million Upsized Initial Public Offering

Fenwick represented Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, in its upsized initial public offering of 8,750,000 shares of its common stock at a public offering price of $16.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $140.0 million. All shares of common stock to be sold in the offering were sold by Maze Therapeutics. In addition, Maze Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,312,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities acted as the joint bookrunning managers for the offering. More information can be obtained from the news announcement.

The Fenwick team included corporate partners Effie Toshav, Amanda Rose, Ryan Mitteness, and Chelsea Anderson, and associates Beth Clarke, Leeza Soulina, Sarah Marshall, Sammi Chen and Phillip Craig; and executive compensation and employee benefits partner Liz Gartland and associates Liza Morgan and Elizabeth Fu.